Compare Regeneron Pharmaceuticals Inc (REGN) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Exxon Mobil Corporation — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Exxon Mobil Corporation trades at $154.89 (market cap $628.83B). The key difference: Exxon Mobil Corporation is far larger — about 8.9× Regeneron Pharmaceuticals Inc's market cap, and Exxon Mobil Corporation pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| REGN | XOM | |
|---|---|---|
Market Cap | $70.79B | $628.83B |
Sector | Health | Energy |
52-Week High | $812.27 | $171.52 |
52-Week Low | $545.46 | $105.83 |
Enterprise Value | $64.74B | $668.06B |
Dividend Yield | 0.56% | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
ExxonMobil (XOM) trades at $148.36, up 0.66% today, with a bullish technical signal from moving averages and a consensus analyst price target of $170.63. Recent quarterly earnings have consistently beaten expectations, though revenue and net income have trended lower from 2022 peaks. The company maintains a strong balance sheet with a debt-to-asset ratio of 8.42% as of 2025, and news highlights its Permian Basin advantages amid volatile oil prices.
XOM offers value through its low-cost production assets and shareholder returns, but faces risks from declining profitability margins and geopolitical oil price swings. Analyst sentiment is mixed with a slight hold bias, while institutional ownership remains substantial. The stock's upside hinges on oil price stability and execution of growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
